Erythropoietin in traumatic brain injury associated acute kidney injury : A randomized controlled trial

Show full item record



Permalink

http://hdl.handle.net/10138/309777

Citation

EPO-TBI Investigators Anzics Clin & Skrifvars , M B 2019 , ' Erythropoietin in traumatic brain injury associated acute kidney injury : A randomized controlled trial ' , Acta Anaesthesiologica Scandinavica , vol. 63 , no. 2 , pp. 200-207 . https://doi.org/10.1111/aas.13244

Title: Erythropoietin in traumatic brain injury associated acute kidney injury : A randomized controlled trial
Author: EPO-TBI Investigators Anzics Clin; Skrifvars, Markus B.
Other contributor: University of Helsinki, Department of Diagnostics and Therapeutics




Date: 2019-02
Language: eng
Number of pages: 8
Belongs to series: Acta Anaesthesiologica Scandinavica
ISSN: 0001-5172
DOI: https://doi.org/10.1111/aas.13244
URI: http://hdl.handle.net/10138/309777
Abstract: Background Acute kidney injury (AKI) in traumatic brain injury (TBI) is poorly understood and it is unknown if it can be attenuated using erythropoietin (EPO). Methods Pre-planned analysis of patients included in the EPO-TBI (ClinicalTrials.gov NCT00987454) trial who were randomized to weekly EPO (40 000 units) or placebo (0.9% sodium chloride) subcutaneously up to three doses or until intensive care unit (ICU) discharge. Creatinine levels and urinary output (up to 7 days) were categorized according to the Kidney Disease Improving Global Outcome (KDIGO) classification. Severity of TBI was categorized with the International Mission for Prognosis and Analysis of Clinical Trials in TBI. Results Of 3348 screened patients, 606 were randomized and 603 were analyzed. Of these, 82 (14%) patients developed AKI according to KDIGO (60 [10%] with KDIGO 1, 11 [2%] patients with KDIGO 2, and 11 [2%] patients with KDIGO 3). Male gender (hazard ratio [HR] 4.0 95% confidence interval [CI] 1.4-11.2, P = 0.008) and severity of TBI (HR 1.3 95% CI 1.1-1.4, P <0.001 for each 10% increase in risk of poor 6 month outcome) predicted time to AKI. KDIGO stage 1 (HR 8.8 95% CI 4.5-17, P <0.001), KDIGO stage 2 (HR 13.2 95% CI 3.9-45.2, P <0.001) and KDIGO stage 3 (HR 11.7 95% CI 3.5-39.7, P <0.005) predicted time to mortality. EPO did not influence time to AKI (HR 1.08 95% CI 0.7-1.67, P = 0.73) or creatinine levels during ICU stay (P = 0.09). Conclusions Acute kidney injury is more common in male patients and those with severe compared to moderate TBI and appears associated with worse outcome. EPO does not prevent AKI after TBI.
Subject: acute kidney injury
creatinine
critical care
erythropoietin
renal insufficiency
traumatic brain injury
THERAPEUTIC HYPOTHERMIA
RENAL-FUNCTION
EPIDEMIOLOGY
PREVENTION
HYPOXIA
COSTS
COMA
EPO
3126 Surgery, anesthesiology, intensive care, radiology
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Erythropoietin_in_traumatic_brain_injury.pdf 569.9Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record